Audit of monitoring of the parameters of metabolic syndrome in patients on clozapine
- J. Tully; C. Sim; R. Hemani; M. Munir; N. Khalil; S. Fahy Audit of monitoring of the parameters of metabolic syndrome in patients on clozapine Psychiatrist
Publication Category: Medications
Increased circulating CC chemokine levels in the metabolic syndrome are reduced by low-dose atorvastatin treatment: evidence from a randomized controlled trial
- B. V. Loughrey; A. McGinty; I. S. Young; D. R. McCance; L. A. Powell Increased circulating CC chemokine levels in the metabolic syndrome are reduced by low-dose atorvastatin treatment: evidence from a randomized controlled trial Clinical endocrinology
Routine screening and rates of metabolic syndrome in patients treated with clozapine and long-acting injectable antipsychotic medications: a cross-sectional study
- A. Lydon; J. Vallely; A. Tummon; S. Maher; S. Sabri; J. McLoughlin; A. Liew; C. McDonald; B. Hallahan Routine screening and rates of metabolic syndrome in patients treated with clozapine and long-acting injectable antipsychotic medications: a cross-sectional study Ir J Psychol Med
Improving and standardizing metabolic screening for people prescribed antipsychotic medication who are at risk of developing metabolic syndrome within the community mental health setting
- D. Hackett; C. Fitzgerald Improving and standardizing metabolic screening for people prescribed antipsychotic medication who are at risk of developing metabolic syndrome within the community mental health setting International journal of mental health nursing
Assessing metabolic syndrome in people with ID (intellectual disabilities) on antipsychotic medication
- A. Carballedo; A. Doran; M. Doyle; S. Flavin; J. Tyrrel; F. Kelly; S. Guerin; P. Dodd Assessing metabolic syndrome in people with ID (intellectual disabilities) on antipsychotic medication Ir J Psychol Med
Exposure-response analyses of liraglutide 3.0 mg for weight management
-
J. P. Wilding; R. V. Overgaard; L. V. Jacobsen; C. B. Jensen; C. W. le Roux
Exposure-response analyses of liraglutide 3.0 mg for weight management Diabetes Obes Metab
Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-Analysis
-
P. M. Ryan; S. Seltzer; N. E. Hayward; D. A. Rodriguez; R. T. Sless; C. P. Hawkes
Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-Analysis J Pediatr
Routine clinical use of liraglutide 3 mg for the treatment of obesity: Outcomes in non-surgical and bariatric surgery patients
-
M. Suliman; A. Buckley; A. Al Tikriti; T. Tan; C. W. le Roux; N. Lessan; M. Barakat
Routine clinical use of liraglutide 3 mg for the treatment of obesity: Outcomes in non-surgical and bariatric surgery patients Diabetes Obes Metab
Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial
-
J. S. Tronieri; T. A. Wadden; O. A. Walsh; R. I. Berkowitz; N. Alamuddin; K. Gruber; S. Leonard; A. M. Chao
Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial Metabolism
Restoration of adipose function in obese glucose-tolerant men following pioglitazone treatment is associated with CCAAT enhancer-binding protein beta up-regulation
- L. A. Powell; P. Crowe; C. Kankara; J. McPeake; D. R. McCance; I. S. Young; E. R. Trimble; A. McGinty Restoration of adipose function in obese glucose-tolerant men following pioglitazone treatment is associated with CCAAT enhancer-binding protein beta up-regulation Clinical science